Endocrinology CME

This free online CME course provides insights into Hypoparathyroidism and how to most effectively treat the condition.

Topics covered in the course include:

• Treatment of hypoparathyroidism
• Barriers to optimal care
• Hypoparathyroidism patient cases

After completing thise course, you will better be able to:

• Describe the pathophysiology and underlying etiologies of hypoparathyroidism and apply these to patient cases.
• Describe the clinical manifestations of hypoparathyroidism and discuss how they may have relevance to treatment targets.
• Identify available therapeutic options for hypoparathyroidism and incorporate these in the development of treatment plans in patient cases.
• Define patient-specific goals related to the management of hypoparathyroidism.

Target Audience: Endocrinologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with hypoparathyroidism.

This free online CME program gives an in-depth look into male Osteoporosis and will help physicians treat this condition better among male patients.

Topics covered in this course include:

• Osteoperosis Epidemiology
• Osteoperosis Risk factors
• Guidance on screening criteria in men
• Osteoperosis Treatment options

After completing this program, you will better be able to:

• Apply screening criteria for male osteoporosis to a given patient
• Describe the criteria for initiation of pharmacotherapy for osteoporosis treatment and prevention and apply them to a patient case
• Identify present pharmacotherapeutic treatments for management of male osteoporosis, and describe their mechanisms of action and place in therapy
• Describe investigational pharmacotherapeutic treatments for management of male osteoporosis, and describe their mechanisms of action and likely place in therapy
• Describe the challenges associated with treating patients with male osteoporosis, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat and prevent osteoporosis and apply the information in optimizing patient care in a patient case

Target Audience: Primary care physicians and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with male osteoporosis.

This online free CME program gives physicians the insights regarding the latest developments around Adult Growth Hormone Deficiency (AGHD) and will help them provide better patient care to those suffering from the condition.

Topics covered in this course include:

• Leading abnormalities and causes of AGHD
• Comorbidities and complications of AGHD
• AGHD patient cases
• Treatment options available for AGHD

After completing this program, you will better be able to:

• Describe the challenges associated with diagnosis of AGHD
• Identify current diagnostic tools for AGHD
• Manage a patient with AGHD’s initial treatment regimen
• Given a patient case, determine how and whether to adjust growth hormone replacement dosing
• Describe present and emerging treatment options for AGHD

Target Audience: Endocrinologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology; and any other healthcare professionals with an interest in or who clinically encounter patients with GHD.

Gaucher disease (GD) is characterized by a deficiency of the lysosomal enzyme glucocerebrosidase, resulting in the accumulation of sphingolipids throughout the body but most manifesting prominently in the bones. GD is subcategorized based on clinical features: type 1 GD is the non-neuronopathic form and affects mainly the inner organs, while types 2 and 3 are the acute and sub-acute neuropathic forms, whose pathology manifests predominantly within central nervous system. GD impacts about 1 in 75,000 births, making it one of the most common lysosomal storage diseases. One of the first of GD’s complications is the chronic anemia and a persistent bleeding risk. Another is the hepatosplenomegaly, which may be a part of the initial clinical presentation, as may the anatomical abnormalities of bone deformities and stunted growth.

By the end of the session the participant will be able to:

• Describe the pathogenesis, clinical presentations, complications, and epidemiology of Gaucher disease including updated recently presented material
• Describe principles and problems regarding screening for and diagnosing Gaucher disease that can applied to patient cases
• Describe emerging therapies for Gaucher disease based on research recently presented
• Design and implement appropriate therapeutic plans for treatment of Gaucher disease based on research recently presented

Target Audience:

The following healthcare professionals: pediatricians, neurologists, endocrinologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Gaucher disease.